Travere Therapeutics (TVTX) Deferred Taxes (2014 - 2017)
Travere Therapeutics' (TVTX) quarterly Deferred Taxes came in at $1.4 million in Q4 2017, up 111.88% YoY from $654129.2 in Q4 2016, and up 157.97% on a QoQ basis from -$2.4 million in Q3 2017.
Travere Therapeutics (TVTX) Deferred Taxes (2014 - 2017) Analysis & Trends
Travere Therapeutics (TVTX) has 4 years of Deferred Taxes data on file, last reported at $1.4 million in Q4 2017.
- Quarterly Deferred Taxes rose 111.88% year-over-year to $1.4 million in Q4 2017, while the trailing twelve-month figure through Sep 2018 was $1.4 million (up 107.12% YoY) and the FY2017 annual result came in at -$6.4 million, up 71.65% from the prior year.
- Deferred Taxes advanced to $1.4 million in Q4 2017, from -$2.4 million in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $28.2 million in Q3 2015 to a low of -$40.0 million in Q1 2015.
- A 4-year average of -$3.9 million and a median of -$2.9 million in 2014 frame the typical range for Deferred Taxes.
- The widest YoY moves for Deferred Taxes: up 111.88% in 2017, down 285.78% in 2017.
- Tracing TVTX's Deferred Taxes over 4 years: stood at -$2.5 million in 2014, then plunged by 53.74% to -$3.8 million in 2015, then plunged by 208.36% to -$11.7 million in 2016, then soared by 111.88% to $1.4 million in 2017.
- The last three Deferred Taxes figures came in at $1.4 million (Q4 2017), -$2.4 million (Q3 2017), and -$3.4 million (Q2 2017), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 1.39 Mn |
| Sep 30, 2017 | -2.39 Mn |
| Jun 30, 2017 | -3.36 Mn |
| Mar 31, 2017 | -2.06 Mn |
| Dec 31, 2016 | -11.66 Mn |
| Sep 30, 2016 | 1.29 Mn |
| Jun 30, 2016 | -7.22 Mn |
| Mar 31, 2016 | -5.07 Mn |
| Dec 31, 2015 | -3.78 Mn |
| Sep 30, 2015 | 28.23 Mn |
| Mar 31, 2015 | -40.02 Mn |
| Dec 31, 2014 | -2.46 Mn |